CMB-305

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameCMB-305
Drug Alias NameLV-305 + G-305combinatorial regimen of LV305 (lentiviral vector encoding NY-ESO-1 gene) and G305 (NY-ESO-1 recombinant protein plus GLA-SE)IDCMB-305CMB-305
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsMelanoma +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesImmune Design
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesImmune Design
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsMelanoma +[8] 

Other Information

ATC CodeN/A
Related LinksN/A